Key Insights Significantly high institutional ownership implies Bristol-Myers Squibb's stock price is sensitive ...

Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of ...

Here are two brilliant options along those lines: CVS Health ( CVS 0.44%) and Bristol Myers Squibb ( BMY -1.03%). Find out ...

Top 15. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the ...

Allogene is ceasing enrollment in a Phase I trial of cema-cel for patients with relapsed or refractory chronic lymphocytic ...

Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...

Bearish flow noted in Bristol Myers (BMY) Squibb with 6,501 puts trading, or 1.1x expected. Most active are Nov-24 59 puts and 11/29 weekly 50 puts, with total volume in those strikes near 3,400 ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Shares of Bristol Myers Squibb Co. BMY shed 1.34% to $59.02 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.29% to 5,983.99 ...

This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...

AbbVie (ABBV) shares slide after its schizophrenia drug failed to meet the goals of its mid-stage trial. Shares of ...